These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 33104036)
21. Perspectives on Spinraza (Nusinersen) Treatment Study: Views of Individuals and Parents of Children Diagnosed with Spinal Muscular Atrophy. Pacione M; Siskind CE; Day JW; Tabor HK J Neuromuscul Dis; 2019; 6(1):119-131. PubMed ID: 30594933 [TBL] [Abstract][Full Text] [Related]
23. Identification of the most relevant aspects of spinal muscular atrophy (SMA) with impact on the quality of life of SMA patients and their caregivers: the PROfuture project, a qualitative study. de Lemus M; Cattinari MG; Pascual SI; Medina J; García M; Magallón A; Dumont M; Rebollo P J Patient Rep Outcomes; 2024 Jul; 8(1):78. PubMed ID: 39044101 [TBL] [Abstract][Full Text] [Related]
24. Impact of a national population-based carrier-screening program on spinal muscular atrophy births. Aharoni S; Nevo Y; Orenstein N; Basel-Salmon L; Ben-Shachar S; Mussaffi H; Sagi-Dain L; Cohen R; Singer A Neuromuscul Disord; 2020 Dec; 30(12):970-974. PubMed ID: 33218846 [TBL] [Abstract][Full Text] [Related]
25. SMN2 and NAIP gene dosages in Vietnamese patients with spinal muscular atrophy. Tran VK; Sasongko TH; Hong DD; Hoan NT; Dung VC; Lee MJ; Gunadi ; Takeshima Y; Matsuo M; Nishio H Pediatr Int; 2008 Jun; 50(3):346-51. PubMed ID: 18533950 [TBL] [Abstract][Full Text] [Related]
26. Understanding European patient expectations towards current therapeutic development in spinal muscular atrophy. Gusset N; Stalens C; Stumpe E; Klouvi L; Mejat A; Ouillade MC; de Lemus M Neuromuscul Disord; 2021 May; 31(5):419-430. PubMed ID: 33752935 [TBL] [Abstract][Full Text] [Related]
28. Incorporating Spinal Muscular Atrophy Analysis by Next-Generation Sequencing into a Comprehensive Multigene Panel for Neuromuscular Disorders. Tan CA; Westbrook MJ; Truty R; Kvitek DJ; Kennemer M; Winder TL; Shieh PB Genet Test Mol Biomarkers; 2020 Oct; 24(10):616-624. PubMed ID: 32721234 [No Abstract] [Full Text] [Related]
29. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Feldkötter M; Schwarzer V; Wirth R; Wienker TF; Wirth B Am J Hum Genet; 2002 Feb; 70(2):358-68. PubMed ID: 11791208 [TBL] [Abstract][Full Text] [Related]
30. The economic burden of spinal muscular atrophy. Armstrong EP; Malone DC; Yeh WS; Dahl GJ; Lee RL; Sicignano N J Med Econ; 2016 Aug; 19(8):822-6. PubMed ID: 27264163 [TBL] [Abstract][Full Text] [Related]
31. A Comparative Study of SMN Protein and mRNA in Blood and Fibroblasts in Patients with Spinal Muscular Atrophy and Healthy Controls. Wadman RI; Stam M; Jansen MD; van der Weegen Y; Wijngaarde CA; Harschnitz O; Sodaar P; Braun KP; Dooijes D; Lemmink HH; van den Berg LH; van der Pol WL PLoS One; 2016; 11(11):e0167087. PubMed ID: 27893852 [TBL] [Abstract][Full Text] [Related]
32. Real-World Data from Nusinersen Treatment for Patients with Later-Onset Spinal Muscular Atrophy: A Single Center Experience. Mendonça RH; Polido GJ; Matsui C; Silva AMS; Solla DJF; Reed UC; Zanoteli E J Neuromuscul Dis; 2021; 8(1):101-108. PubMed ID: 33074187 [TBL] [Abstract][Full Text] [Related]
33. RegistrAME: the Spanish self-reported patient registry of spinal muscular atrophy. Cattinari MG; de Lemus M; Tizzano E Orphanet J Rare Dis; 2024 Feb; 19(1):76. PubMed ID: 38373977 [TBL] [Abstract][Full Text] [Related]
34. Sex Difference in Spinal Muscular Atrophy Patients - are Males More Vulnerable? Sun J; Harrington MA; Porter B; J Neuromuscul Dis; 2023; 10(5):847-867. PubMed ID: 37393514 [TBL] [Abstract][Full Text] [Related]
35. A multi-source approach to determine SMA incidence and research ready population. Verhaart IEC; Robertson A; Leary R; McMacken G; König K; Kirschner J; Jones CC; Cook SF; Lochmüller H J Neurol; 2017 Jul; 264(7):1465-1473. PubMed ID: 28634652 [TBL] [Abstract][Full Text] [Related]
36. Population screening for spinal muscular atrophy: A mixed methods study of the views of affected families. Boardman FK; Young PJ; Griffiths FE Am J Med Genet A; 2017 Feb; 173(2):421-434. PubMed ID: 27792846 [TBL] [Abstract][Full Text] [Related]
37. Epidemiological investigation of spinal muscular atrophy in Japan. Ito M; Yamauchi A; Urano M; Kato T; Matsuo M; Nakashima K; Saito K Brain Dev; 2022 Jan; 44(1):2-16. PubMed ID: 34452804 [TBL] [Abstract][Full Text] [Related]
38. A qualitative study of perceptions of meaningful change in spinal muscular atrophy. McGraw S; Qian Y; Henne J; Jarecki J; Hobby K; Yeh WS BMC Neurol; 2017 Apr; 17(1):68. PubMed ID: 28376816 [TBL] [Abstract][Full Text] [Related]
39. Nusinersen treatment of spinal muscular atrophy - a systematic review. Albrechtsen SS; Born AP; Boesen MS Dan Med J; 2020 Aug; 67(9):. PubMed ID: 32800069 [TBL] [Abstract][Full Text] [Related]
40. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand? Chen TH Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392694 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]